Statement: In total, across both cohorts of the primary trial, there were at least 2 patients with a fever.
Primary_evidence: Adverse Events 1:   Total: 2/6 (33.33%)   Febrile neutropenia * 1/6 (16.67%)   Neutropenia * 0/6 (0.00%)   Thrombocytopenia * 1/6 (16.67%)   Diarrhoea * 0/6 (0.00%)   Pyrexia * 0/6 (0.00%)   Thrombosis in device * 1/6 (16.67%)   Fatigue * 0/6 (0.00%)   Mucosal inflammation * 0/6 (0.00%)   Device deployment issue * 0/6 (0.00%)   Hepatocellular injury * 1/6 (16.67%)   Cholecystitis * 1/6 (16.67%) Adverse Events 2:   Total: 2/6 (33.33%)   Febrile neutropenia * 1/6 (16.67%)   Neutropenia * 1/6 (16.67%)   Thrombocytopenia * 0/6 (0.00%)   Diarrhoea * 0/6 (0.00%)   Pyrexia * 0/6 (0.00%)   Thrombosis in device * 1/6 (16.67%)   Fatigue * 0/6 (0.00%)   Mucosal inflammation * 0/6 (0.00%)   Device deployment issue * 0/6 (0.00%)   Hepatocellular injury * 0/6 (0.00%)   Cholecystitis * 0/6 (0.00%)